Abstract
Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.
Current Drug Targets
Title:Proteomic Classification of Breast Cancer
Volume: 13 Issue: 12
Author(s): Dalia Kamel, Bernadette Brady, Adel Tabchy, Gordon B. Mills and Bryan Hennessy
Affiliation:
Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.
Abstract: Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
Export Options
About this article
Cite this article as:
Kamel Dalia, Brady Bernadette, Tabchy Adel, B. Mills Gordon and Hennessy Bryan, Proteomic Classification of Breast Cancer, Current Drug Targets 2012; 13 (12) . https://dx.doi.org/10.2174/138945012803530080
DOI https://dx.doi.org/10.2174/138945012803530080 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Withdrawal Notice: Computational Druglikeness Assessment, Synthesis, Characterization and In vitro Biological Activity Evaluation of some Novel Mixed Metal Complexes of 2-(butan-2-ylidene) Hydrazinecarbothioamide
Combinatorial Chemistry & High Throughput Screening Cell Cycle Checkpoint Genes and Aneuploidy: A Short Review
Current Genomics Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
Current Pharmaceutical Design Epigenetic Regulation and Promising Therapies in Colorectal Cancer
Current Molecular Pharmacology Paris Saponin VII Induces Apoptosis and Cell Cycle Arrest in Erythroleukemia Cells by a Mitochondrial Membrane Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Structure, Biological Properties and Applications of Marine-derived Polysaccharides
Current Organic Chemistry Meet Our Editorial Board Member:
Current Drug Targets Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Recent Patents in Autophagy and Immune Response
Recent Patents on Inflammation & Allergy Drug Discovery Epigenetic Regulation in Particulate Matter-Mediated Cardiopulmonary Toxicities: A Systems Biology Perspective
Current Pharmacogenomics and Personalized Medicine Anti-carcinogenic Effect of Cathepsin K Inhibitor, Odanacatib with a Low Dose of Cisplatin Against Human Breast Carcinoma MCF-7 and MDA-MB231 Cells
Current Cancer Therapy Reviews Mechanisms and Immunological Roles of Apoptosis in Molluscs
Current Pharmaceutical Design Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
Current Drug Safety